Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 230 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Malignant Pleural Disease Clear all
Terminated Phase 1 Interventional

A Study of SGN-CD228A in Advanced Solid Tumors

NCT04042480
View directory record Official record
Conditions
Cutaneous Melanoma, Pleural Mesothelioma, HER2 Negative Breast Neoplasms, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
SGN-CD228A
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 6, 2026, 4:55 PM EDT
Completed No phase listed Observational

Collecting Tumor Samples From Patients With Gynecological Tumors

NCT00897442
View directory record Official record
Conditions
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Childhood Embryonal Rhabdomyosarcoma, Childhood Malignant Ovarian Germ Cell Tumor, Endometrioid Stromal Sarcoma, Gestational Trophoblastic Tumor, Malignant Mesothelioma, Malignant Ovarian Epithelial Tumor, Melanoma, Neoplasm of Uncertain Malignant Potential, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Paget Disease of the Vulva, Recurrent Cervical Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer, Stage I Vaginal Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Cervical Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage II Vaginal Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Cervical Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Uterine Corpus Cancer, Uterine Corpus Leiomyosarcoma, Vulvar Squamous Cell Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
187
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

NCT00002475
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer
Interventions
allogeneic tumor cell vaccine, autologous tumor cell vaccine, recombinant interferon alfa, recombinant interferon gamma, sargramostim, cyclophosphamide
Biological · Drug
Lead sponsor
St. Vincent Medical Center - Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 6, 2026, 4:55 PM EDT
Terminated Phase 3 Interventional Results available

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

NCT04158141
View directory record Official record
Conditions
Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8, Stage IB Pleural Malignant Mesothelioma AJCC v8, Stage II Pleural Malignant Mesothelioma AJCC v8, Stage IIIA Pleural Malignant Mesothelioma AJCC v8
Interventions
Carboplatin, Cisplatin, Decortication, Intensity-Modulated Radiation Therapy, Pemetrexed, Pemetrexed Disodium, Pencil beam scanning proton therapy, Pleurectomy
Drug · Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Coral Gables, Florida • Chicago, Illinois • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 4 Interventional

Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter

NCT00978939
View directory record Official record
Conditions
Pleural Effusion, Malignant
Interventions
Standard Drainage Instructions, Aggressive Drainage Instructions
Other
Lead sponsor
Duke University
Other
Eligibility
19 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma

NCT04525859
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Safety, Expansion Cohort
Biological
Lead sponsor
Oncovir, Inc.
Industry
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 6, 2026, 4:55 PM EDT
Active, not recruiting Phase 1 Interventional

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

NCT04577326
View directory record Official record
Conditions
Malignant Pleural Mesothelioma (MPM)
Interventions
cyclophosphamide, CAR T cells
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Recruiting Not applicable Interventional

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

NCT06037941
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
E-Nose testing, Research blood
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
30 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

NCT01085630
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
pemetrexed disodium, clinical observation
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
145
States / cities
Scottsdale, Arizona • San Francisco, California • Hartford, Connecticut + 104 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

NCT01112293
View directory record Official record
Conditions
Pleural Malignant Mesothelioma
Interventions
GC1008
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma

NCT01503177
View directory record Official record
Conditions
Recurrent Malignant Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma, Stage II Malignant Mesothelioma, Stage III Malignant Mesothelioma, Stage IV Malignant Mesothelioma
Interventions
oncolytic measles virus encoding thyroidal sodium iodide symporter, laboratory biomarker analysis, single photon emission computed tomography, computed tomography
Biological · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma

NCT01675765
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Immunotherapy plus chemotherapy, Immunotherapy with cyclophosphamide plus chemotherapy
Biological
Lead sponsor
Aduro Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
5
States / cities
San Francisco, California • Tampa, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

NCT00564733
View directory record Official record
Conditions
Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
carboplatin, docetaxel, gemcitabine hydrochloride, paclitaxel, computed tomography, positron emission tomography, fludeoxyglucose F 18, imaging biomarker analysis
Drug · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

NCT01069328
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer
Interventions
Nexavar (Sorafenib, BAY43-9006), Bevacizumab, Paclitaxel, Carboplatin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

NCT00231465
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
docetaxel (Taxotere®), ZD1839
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
70 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 4 Interventional

Non-small Cell Lung Cancer Registry

NCT00099541
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
101
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Anaheim, California + 93 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2009 · Synced Oct 6, 2026, 4:55 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Talc Outpatient Pleurodesis With Indwelling Catheter

NCT03973957
View directory record Official record
Conditions
Pleural Effusion, Pleural Diseases, Malignant Pleural Effusion
Interventions
Indwelling pleural catheter placement, Fentanyl Citrate, Talc Slurry, Drainage collection bag
Device · Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional

S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery

NCT00003723
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
gemcitabine hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 6, 2026, 4:55 PM EDT
Terminated Phase 1Phase 2 Interventional

Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer

NCT00281125
View directory record Official record
Conditions
Non-Small Cell Lung Cancer and Pleural Mesothelioma
Interventions
PTK787 and Pemetrexed with or without Cisplatin
Drug
Lead sponsor
Nevada Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 6, 2026, 4:55 PM EDT
Recruiting Early Phase 1 Interventional

Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion

NCT06184321
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Alteplase, Placebo Administration
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

NCT00052338
View directory record Official record
Conditions
Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
gemcitabine hydrochloride, carboplatin, bortezomib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 6, 2026, 4:55 PM EDT
Active, not recruiting Phase 2 Interventional

Intrapleural Catheter Daily Versus Three Times a Week Drainage

NCT00761618
View directory record Official record
Conditions
Advanced Cancer, Pleural Effusion
Interventions
Intrapleural catheter (IPC) drained, IPC Placement, Chest X-Ray
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Completed No phase listed Observational

Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite

NCT00897247
View directory record Official record
Conditions
Malignant Mesothelioma, Pulmonary Complications
Interventions
microarray analysis, protein expression analysis, proteomic profiling, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
25 Years to 80 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

NCT00003263
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
recombinant interferon alfa, cisplatin, surgical procedure, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
3
States / cities
Marrero, Louisiana • Philadelphia, Pennsylvania • Newport News, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 6, 2026, 4:55 PM EDT